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Objectives. This study was designed to test the hypothesis that 
low molecular weight heparin may lessen the severity of ischemic 
events in patients with unstable angina. 
Background. Unstable angina is a thrombotic process that 
requires intensive medical treatment. Although current tl~at. 
ments can reduce the number of complications, serious bleeding 
continues to occur. Nadroparin calcium, a low molecular weight 
heparin, seems to he a safe therapeutic agent hat does not require 
laboratory monitoring. 
Methods. A total of 219 patients with unstable angina entered 
the study at a mean time of 6.17 h after the last episode of rest 
pain. Patients were randomized to receive aspirin (200 rag/day 
[group A]), aspirin plus regular heparin (400 lU/kg body weight 
per day intravenously and titered by activated partial thrombo- 
plastin time [group B]) and aspirin plus low molecular weight 
heparin (214 UIC/kg anti-Xa twice daily subcutaneously [group 
C]). The major end points determined for the in-hospital period 
were 1) recurrent angina, 2) myocardial infarction, 3) urgent 
revasculaHzation, 4) major bleeding, and 5) death. Minor end 
points were 1) silent myocardial ischemia, and 2) minor bleeding. 
Event rates were tested by chi-square analysis. 
Results. Recurrent angina occurred in 37%, 44% and 21% of 
patients in groups A, B and C, respectively, and was significantly 
less frequent in group C than in either group A (odds ratio 2.26, 
95% confidence interval [CI] I to 5.18, p = 0.03) or group B (odds 
ratio 3.07, 95% CI 1,36 to 7.00, p = 0.002). Nonfatal myocardial 
infarction was present in seven patients in group A, four in group 
B and none in group C (group B vs. A, p = 0.5; group C vs. A, p "- 
0.01). Urgent revascularization was performed in nine patients in 
group A, seven in group B and one in group C (C vs. A, p = 0.01). 
Two episodes of major bleeding occurred in group B. Silent 
myocardial ischemia was present in 38%, 41% and 25% of patients 
in groups A, B and C, respectively, and was significantly less 
frequent in group C than group B (odds ratio 2.12, 95% CI 0.97 to 
4.69, p = 0.04). Minor bleeding was detected in 10 patients in 
group B, I patient in group C (B vs. C, p = 0.01) and no patient 
in group A (A vs. B, p = 0.003). 
Conclusions. In this study, treatment with aspirin plus a high 
dose of low molecular weight heparin during the acute phase of 
unstable angina was significantly better than treatment with 
aspirin alone or aspirin plus regular beparin. 
(JAm Cog Cardiol 1995;26:313-8) 
Coronary studies suggest that unstable angina results from 
thrombus formation and platelet aggregation. These throm- 
botic processes are generally mediated by thrombin, depen- 
dent on the action of platelets and not completely responsive 
to conventional therapy with aspirin and heparin (1). Never- 
theless, pharmacologic studies (2-4) using antithrombotic 
agents in patients with unstable angina have demonstrated 
their beneficial effect in this coronary syndrome. Clinical 
studies (2-5) comparing aspirin and heparin in unstable angina 
have shown no significant differences among heparin, aspirin 
or a combination ofboth drugs. 
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In a pre~i~us tudy (6) we demonstrated biochemical 
differences between patients with an acute myocardial infarc- 
tion and patients w:,th unstable angina or silent myocardial 
ischemia. We observed that thrombotic leactant markers were 
significantly elevated in patients with unstable angina nd also 
during episodes of silent myocardial ischemia. Other studies 
(7-9) have also shown that local phenomena such as vasospasm 
may precipitate myocardial ischemia. Therefore, thrombosis 
and thrombolysis appear to be important mechanisms in
unstable angina nd silent ischemia. 
Low molecular weight heparin is absorbed onto the vascular 
endothelium and results in the increased release of tissue 
plasminogen activator (10,11). It has high antifactor Xa and 
antithrombin activities. The drug may have interference with 
platelets, reduces thrombin-induced platelet aggregability, 
causes less enhancement of aggregation i duced by adenosine 
diphosphate (12) and significantly reduces fibrinogen levels in 
patients with a coronary artery syndrome (13,14). 
The purpose of the present study was to determine whether 
a high dose of low molecular weight heparin combined with 
0735-1097/95/$9.50 
©1995 by the American College of Cardiology 0735-1097(95)00184-6 
314 GURFINKEL ET AL. JACC Vol. 26, No. 2 
LOW MOLECULAR WEIGHT HEPARIN IN UNSTABLE ANGINA August 1995:313-8 
aspirin is more beneficial than aspirin alone, or aspirin plus 
regular heparin, during the acute phase of unstable angina. 
Methods  
The study was a prospective, randomized, single-blind trial 
of antithrombotie herapy for patients admitted to the coro- 
nary care unit with acute chest pain due to unstable angina. A 
total of 219 patients gave written informed consent and were 
randomized. 
Inclusion criteria. The following inclusion criteria were 
used: 1) Men or women >21 years old. 2) Unstable angina, 
defined as recent onset or prolonged (>-10 min), spontaneous 
rest pain occurring within 24 h of randomization. 3) Evidence 
of underlying ischemic heart disease as shown by at least one or 
more of the following: a) electrocardiographic (ECG) ischemic 
changes; b) previous documented myocardial infarction; c) 
previous coronary artery bypass urgery; d) history of typical 
exertional angina; e) previous coronary angiography showing 
>-70% lumen narrowing in any corona~ artery; f) angina at 
rest without acute ECG changes (diagnosed by two cardiolo- 
gists); and g) positive stress test for angina or ST segment 
depression i  the last month, or both. 4) Informed consent. 
Exclusion criteria. The following exclusion criteria were 
used: I) Acute Q or non-Q wave myocardial infarction. 2) Left 
bundle branch block. 3) Angina due to pulmonary edema; 
tachyarrhythmia; valvular heart disease; status postacute or 
postsubacute myocardial infarction (<-12 weeks after infarc- 
tion); thyrotoxicosis; hypertension; anemia (hemoglobin 
<11 g/dl). 4) Angioplasty within 3 months. 5) Contraindica- 
:ions to anticoagu!ation r nonsteroid anti-inflammatory 
drugs. 6) Use of anticoagulant drugs. 7) Presence of a terminal 
disease. 8) Pregnancy. 9) Implanted pacemaker. 
Design of the study. Patients were randomized to one of 
three groups: group A = aspirin alone (200 mg/day orally) in 
accordance with the recommendations f the Third American 
College of Chest Physicians Consensus Conference on Anti- 
thrombotic Therapy (15) plus saline solution infusion and bolus 
as placebo for heparin; group B = aspirin (200 mg/day orally) plus 
continuous infusion of intravenous heparin (400 IU/kg body 
weight per day), using a weight-adjusted heparin nomogram) 
preceded by a bolus of 5,000 IU of heparin designed to raise the 
activated partial thromboplastin me to t~ce the control evel 
and titered aily; and group C = aspirin (200 mJday orally) plus 
214 units Institute Choay [UIC]/kg anti-Xa of low molecular 
weight heparin (CY 216 nadroparin calcium) twice daily subcu- 
taneously and saline solution infusion and bolus as placebo for 
heparin. Patients with previous aspirin use were also randomized 
if this drug was being taken irregularly. In all patients the 
antithrombotic herapy was discontinued by day 5 to 7 of admis- 
sion (in-hospital period) or if a primary end point (see later) was 
reached or a definitive decision was made to perform an inter- 
ventional procedure or provide ongoing medical treatment. 
Medical treatment. Treatment with standard antianginal 
iherapy (beta-adrenergic blocking agents, calcium channel 
blockers or intravenous nitrates, alone or in combination), was 
begun immediately c,n randomization. Continuation ofpread- 
mission medications was recommended; the dosage was in- 
creased or another antianginal drug was added. The doses 
were increased as tolerated to obtain a systolic blood pressure 
of -<130 mm Hg and a heart rate of -<60 beats/min. 
Laboratory tests. Serum total creatine kinase and its MB 
fraction were analyzed every 6 h for the initial 24 h to exclude 
acute myocardial infarction, and measurements were repeated 
every 12 h thereafter. Activated partial thromboplastin times 
were also obtained once daily or more, according to the 
recommendations f the hemostasis team, and were titered by 
activated partial thromboplastin ime until maintained attwo 
times the normal values. An activated partial thromboplastin 
time basal control measurement was also obtained in patients 
in both groups A and C. Except for this control measurement, 
coagulation variables were not measured routinely in patients 
receiving low molecular weight heparin (group C). 
ECG monitoring. The ST segment was monitored contin- 
uously during the 1st 48 h of admission with the use of two 
channels of a Siemens Sirecust 960 electrocardiograph. Leads 
were positioned according to the jeopardized area in patients 
presenting with acute ECG ischemic hanges and positioned 
according to standard locations in patients without ischemic 
changes. The device was programmed to detect ST segment 
alteration; an alarm signal sounded if an ST segment shift 
>2 ram.. appeared. At least one complete 12-lead ECG was 
obtained in each patient daily. 
Coronary angiography. Coronary angiography, when indi- 
cated, was performed a mean of 4.73 days after andomization. 
"Ibis delay was in accord with current practice in our institution 
and was not influenced by the patients' inclusion in the trial. 
Primary end points. The following events were defined as 
primary end points: 1) Recurrent angina, defined as chest pain 
at rest hat lasted >-10 min with or without ST segment changes 
but under an appropriate anti-ischemic s hedule, with a heart 
rate <60 beats/min and systolic blood pressure <130 mm Hg. 
2) Acute myocardial infarction, defined as the sudden develop- 
ment of new Q waves or non-Q wave ECG changes associ- 
ated with increased levels of creatine kinase MB fraction 
>50 IU/liter (normal reference range 0 to 25 IU/liter). 3) 
Urgent intervention (coronary angioplasty or bypass urgery) 
when symptoms and signs were uncontrolled espite a full 
medical schedule (five drugs, including antiplatelet agents, 
anticoagulant agents, beta-adrenergic blocking agents, calcium 
channel antagonists and intravenous nitroglycerin). 4) Major 
bleeding, defined as a decrease in hemoglobin >-2 g/dl or the 
need for transfusion, or both. 5) Death. 
Seconda~ end points. Two events were defined as second- 
ary end points: 1) Silent ischemia, defined as an episode of 
ECG changes without pain registered when th," alarm signal 
sounded. It was considered an unsatisfactory outcome when it 
was present during the 1st 48 h. Patients with this finding were 
not excluded from the study but their therapy was adjusted 
intensively. 2) Minor bleeding, defined as spontaneous hema- 
tomas or bleeding at the puncture sites. 
JACC Vol. 26, No. 2 GURFINKEL El" AL. 315 
August 1995:313-8 LOW MOLECULAR WEIGHT HEPARIN IN UNSTABLE ANGINA 
Statistical analysis. A sample size of 315 patients was 
based on a projected 36% rate of events (mortality 1%, 
myocardial infarction 3%, recurrent angina 17%, silent myo- 
cardial ischemia 13%, bleeding 2%) to detect a50% reduction 
in end point (confidence l vel or 1 alpha 95% and power of 1 
beta 80%). 
Analysis ~as based on intention to treat. Comparisons of 
baseline characteristics and events were performed by using a 
chi-square statistics or t test, as appropriate. A two-tailed 
Fisher exact est was used if there was an expected value of <5. 
Odds ratios were computed by Cornfield 95% confidence limit. 
An exploratory analysis of data was performed with Epi Info 
Version 5.0 (World Health Organization, Geneva, Switzer- 
land). A p value < 0.05 was considered significant. 
Resu l ts  
Of the 663 patients with angina who were evaluated for 
entry into the study between May 1993 and July 1994, 444 did 
not meet he criteria for eligibility. All patients were admitted 
because of unstable angina with chest pain in tlte previous 24 h. 
Patients ->80 years of age, those who recently underwent 
angioplasty or bypass urgery, those with a Q or non-Q wave 
acute myocardial infarction or angina after acute myocardial 
infarction and those receiving long-term and appropriate aspi- 
rin treatment were the basis for nearly 100% of the exclusions. 
Of the 219 patients randomized, 8 were later excluded--6 
because their participation was refused by their physician and 
2 because they subsequently had normal coronary angio- 
graphic findings. 
Of the remaining 211 patients, 73 (group A) were randomly 
assigned to receive aspirin, 70 (group B) to receive aspirin plus 
intravenous heparin and 68 (group C) to receive aspirin plus 
low molecular weight heparin. 
Groups were similar with respect to all pretreatment char- 
acteristics, including age, gender and clinical, ECG and angio- 
graphic features (Tables 1 and 2). At the time of admission 121 
patients were taking beta-blockers, 89 were taking calcium 
channel antagonists, 143 were taking aspirin, 32 were taking 
angiotensin-converting e zyme inhibitors and 72 were taking 
nitrates. 
Angiography was not required in 53 patients (25%) who 
were satisfactorily discharged in accordance with our institu- 
tional criteria, which did not indicate aneed for this procedure. 
Patients who did not reach a deft,ted end point were 
discharged between 5 and 7 days after admission, free of 
symptoms and instructed to follow conventional therapy with 
aspirin and their baseline medications. Thi,~; point was achieved 
by 41% of patients in group A, 37% in group B and 78% in 
group C. The remaining patients all reached an end point 
within this period (27% within the 1st 48 h; Table 3). 
Recurrent chest pain despite full therapy led to urgent 
coronary angiography in 17 patients (11%). Three-vessel cor- 
onary disease was common in the three groups (25%, 42% and 
44%, respectively). Left main coronary artery disease associ- 
ated with one- or two-vessel disease was present in 13%, 8% 
Table l. Baseline Characteristics in the Three Study Groups 
Group A Group B Group C p 
(n = 73) (n = 70) (n = 68) Value 
Male 53 (73%) 52 (74%) 46 (68%) 0.6 
Mean age (yr) 64.1 63.5 62.6 0.7 
Smoker 29 31 29 0.8 
Hypertension 48 51 47 0.6 
Diabetes 13 13 12 0.9 
Hypercholesterolemia 33 25 26 0.4 
Prior AMI 23 26 22 0.7 
Prior PTCA or CABG 22 29 21 0.2 
Prior angina* 41 38 27 0.8 
Calcium channel blocker 30 30 29 0.9 
Beta-blocker 41 4i 39 0.9 
ACE inhibitor i2 10 10 0.7 
*>180 days of evolution. Unless otherwise indicated, ata are expressed as
number (%) ef patients. ACE = angiotensin-converting enzyme; AMI = acute 
myocardial int~arction; CABG = coronary artery bypass graft; Group A = 
patients receiving aspirin alone; Group B = patients receiving aspirin plus 
intravenous heparin; Group C = patients receiving aspirin plus low molecular 
weight heparin; PTCA = pereutancous transluminal coronary angioplasty. 
and 15% of patients, respectively, ineach group (Table 2). All 
indexes tudied were somewhat unequally distributed among 
the groups (p = NS). 
Primary end points. Major events occurred in 59%, 63% 
and 22% of patients in groups A, B and C, respectively, and 
were significantly less frequent in group C than in group A 
(odds ratio 5.06, 95% CI 2.28 to 11.39, p = 0.00001) or group 
B (odds ratio 5.63, 95% CI 2.50 to 12.81, p = 0.00001). 
Recurrent angina occurred in 37%, 44% and 21% of patients 
in groups A, B and C, respectively, and was significantly ess 
frequent in group C than in group A (odds ratio 2.26, 95% CI 
1 to 5.18, p = 0.03) or group B (odds ratio 3.07, 95% CI 1.36 
to 7.00, p = 0.002). 
Nonfatal myocardial infarction was present in seven pa- 
tients in group A, four in group B and none in group C (group 
C vs. A, p = 0.01; group B vs. A, p = 0.5). Urgent revascular- 
ization was performed in nine patients (12%) in group A, 
Table 2. Randomization a d Angiographic Data in the Three 
Study Groups 
Group A Group B Group C 
(n = 73) (n = 70) (n = 68) 
Mean time to 6.05 6.4 6.06 
randomization (h) 
Mean time to 5 4.2 5 
angiography (days) 
CAD 
1-vessel 13/55 (24%) 10/55 (18%) 10/48 (21%) 
2-vessel 11/55 (20%) 18/55 (33%) 10/48 (21%) 
3-vessel 24/55 (44%) 23/55 (42%) 21/48 (44%) 
Left main with 1- 7/55 (13%) 4/55 (7%) 7/48 (14.5%) 
or 2-vessel 
Unless otherwise indicated, data are expressed as number (%) of patienk~. 
Definitions of groups as in Table 1. CAD = coronary artery disease. 
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Table 3. Duration of the Study (in-hospital) for the Three 
Study Groups 
End Points End Points Discharged 
(1st 48 h)* (day 2 to 6) (day 5 to 7) 
Group No. % No. % No. % 
A(n = 73) 22 30 21 29 30 41 
B (n =70) 25 36 19 27 26 37 
C (n =68) 11 16 4 6 53 78 
*Primary end points were observed in the 1st 48 h in 27% of patients. Dam 
are expressed as number o percent of patients. Definitions ofgroups as in Table 1. 
seven (10%) in group B and one patient (1.5%) in group C 
(group C vs. A, p = 0.01). There were two major bleeding 
episodes in group B (hematuria n one patient and hemoptysis 
in the other) and no deaths in any group (Table 4). 
Secondary end points. There was a statistically significant 
difference in total secondary events. There were 28 (38%), 39 
(56%) and 18 (26.5%) such events in groups A, B and C, 
respectively. A statistically significant difference was found 
between groups C and B (odds ratio 3.49, 95% CI 1.61 to 7.64, 
p = 0.0004) and between groups A and B (p = 0.03). 
A total of 8,234 hours of continuous ECG recording was 
obtained. The mean time between admission and the first 
episode of silent ischemia was 420 _ 143 min. Silent myocar- 
dial ischemia was present in 38%, 41% and 25% of patients in 
groups A, B ':rid C, respectively, and was significantly less 
frequent in group C than group B (odds ratio 2.12, 95% CI 0.97 
to 4.69, p = 0.04). Minor bleeding was detected in 10 patients 
in group B (14.5%), 1 patient (1.5%) in group C (p = 0.01) 
(Table 5) and no patient in group A (group A vs. B, p = 0.003). 
Anticoagulation state. The total duration of anticoagnla- 
tion in group B was 5,424 h. With use of our nomogram of 
infusion the appropriate activated partial thromboplastin time 
level could be maintained uring 3,675 h (68% during the 
in-hospital stay). The total number of hours below the target 
activated Fartial thromboplastin time was 1,128 (21%); 621 h 
(11.5%) w,~re above this target level. In group B one case of 
hematuria occm~ed when the activated partial thromboplastin 
time was in the appropriate range, and hemoptysis occurred in 
another patient when the activated partial thromboplastin ime 
was <2.5 times its basal evel. 
Complications. Adverse effects were infrequent in tb~s 
study (Table 6). 
Table 4. Primary End Points* 
D iscuss ion  
In this prospective, single-blind, randomized trial of pa- 
tients with unstable angina, a high dose of low molecular 
weight heparin plus aspirin was superior to either regular 
unfractionated heparin plus aspirin or aspirin alone in reduc- 
ing the number of major and minor events. 
The angiographic features of our patients merit some 
discussion. Globally 43% had three-vessel coronary disease 
and 11% had left main disease, in association with one- or 
two-vessel disease. These phenomena c n influence the prog- 
nosis of unstable angina and could have affected our results. 
However, because the findings were equally distributed among 
patient groups, the significance of the differences i  maintained. 
Aspirin. There are important observations (16,17) support- 
ing the concept that aspirin is an excellent antithrombotic drug 
during the early phase of this coronary syndrome. However, 
the rate of recurrence of ischemia in the patients in our study 
receiving aspirin was still very high. Vascular thrombi may be 
resistant to aspirin for a variety of reasons. Disrupted athero- 
matous lesions activate platelets by means of thrombin, an 
aspirin-independent agonist. Thrombin located in thrombi s 
protected from inactivation by heparin and aspirin because it is 
present in a configuration capable of proteolytically activating 
platelets and cleaving fibrinogen but is inaccessible to heparin 
(18). 
In most previous trials the choice of aspirin dose was 
empiric. For example, in the RISC study (4) the dose was 
75 mg/day, in the Veterans Administration Cooperative Study 
(19) it was 324 mg/day and in the study of Th6roux et al. (20) 
it was 325 mg twice daily. Although increasing the dose of 
aspirin may influence other components of interactions be- 
tween platelets and endothelium, larger doses have other 
potentially deleterious effects (21). 
In the study of Th6roux et al. (20) the prevalence of 
three-vessel disease was much less than that in our study. Thus, 
our patients had less favorable anatomy, perhaps making our 
findings even more significant. In fact, treatment for patients 
with unstable angina should consider the use of different doses, 
taking into account the different risk factors in this group. Our 
data show that 200 rag/day of aspirin is less effective than 
200 mg/day combined with low molecular weight heparin. 
Heparin. The usefulness of heparin in acute angina has 
been documented for >10 years (22). We thought hat the 
Revascularization 
Total Events Recurrent Angina Major Bleeding AMI Procedure 
P p P P P 
Group No. % Value No. % Value No. % Value No. % Value No. % Value 
A (n = 73) 43 59 0.00001t 27 37 0.03t 0 -- 0.2~: 7 9.5 0.01t 9 12 0.01t 
B (n = 70) 44 63 0.00001§ 31 44 0.002§ 2 3 0.4§ 4 6 0.511 7 10 0.811 
C (n = 68) 15 22 -- 14 21 -- 0 -- -- 0 -- 0.I§ 1 1.5 0.07§ 
*No deaths occurred in any group, i'Difference b tween groups Cand A. :[:Difference b tween groups A arid B. §Difference b tween groups Cand B. IIDifference 
between groups Band A. Data re expressed as number o  percent ofpatients. Definitions ofgroups and abbreviation as in Table 1. 
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Table S. Secondary End Points 
Silent lsehemia Minor Bleeding 
P P 
Group No. % Value No. % Value 
A(n = 73) 28 38 0.8* 0 0 0.003* 
B (n = 70) 29 41 0.04t 10 14 0.0It 
C(n =68) 17 25 0.1, 1 1~ 0.~ 
*Difference between groups A and B. tDifference between groups B and 12. ,Difference between groups C and A. 
Data are expressed as number or percent of patients. Definitions of groups as in Table 1. 
maximal benefit would be obtained in the acute phase of the 
syndrome when therapy was initiated early. Nevertheless, the 
vast majority of events occurred within the 1st 48 h in all 
groups. Intravenous heparin is associated with many difficulties 
including the loss of heparin effect and maintenance of the 
therapeutic ranges (23-25). The GUSTO study (26) also 
recently demonstrated the frequency with which heparin falls 
to a subtherapeutie range as reflected by activated partial 
thromboplastin time times. In our study we decided to use a 
weight-adjusted nomogram of infusion to achieve optimal 
therapeutic ranges in the search for better esults, Heparin is 
also affected by various substances. Platelet products, such as 
antiheparin factor (PF-4) (27), may interfere with heparin, as 
do vitronectin (28), fibroneetin, lipoproteins (29) and vascular 
surfaces (30). There is evidence (31) that aggregation could be 
induced under certain conditions by using heparin with high 
molecular weight. 
Low molecular weight heparin. Low molecular weight hep- 
arin is characterized bya specific anti-Factor Xa effect, induc- 
ing only a small prolongation of the general cloning test, such 
as activated partial thromboplastin time, prothrombin time 
and antithrombin activity when a high dose is used (32). Low 
molecular weight heparin and regular heparin have many 
common properties. It would be reasonable to assume that 
other easons may explain these results: 
1) It is known that low molecular weight heparin has a much 
lower affinity for plasma nd matrix proteins, a demonstrated 
superior bioavailability and a longer half-life (33) than regular 
heparin~ and it can be administered without laboratory 
monitoring (34). 2) Unfractionated heparin has a delay until 
the target activated partial thromboplastin time is reached. 
Table 6. Complications 
Complication Group A Group B Group C 
Spontaneous hematoma 0 1 0 
Abdominal pain 0 0 0 
Thrombocytopenia 0 0 0 
Noncardiac death 0 0 0 
Stroke 0 0 0 
Related to cardiac 0 9 1" 
catheterization 
Study drug discontinued 0 0 0 
Another effect 0 0 0 
*p = 0.004, group C versus group B. Definitions of groups as in Table 1. 
3) Because this is a combination of two antithrombotic drugs, 
there may exist pharmacologic interactions not described at 
the moment. 
Limitations of this study. Although this study demon- 
strated the safety of low molecular weight heparin in patients 
with unstable angina, because some principal outcomes may be 
subjective, a very important limitation of this trial is its 
single-blind nature. 
The originally projected sample size of the trial was 315 
patients to obtain a significant reduction of events. After 180 
patients had been included, the Data Review Board Commit- 
tee of the investigation performed an interim analysis that 
revealed an unexpected significant reduction of ischemic 
events (more than the initial 25% expected in the low molec- 
ular weight arm) in group C and significantly more bleeding 
complications ingroup B. The termination of the study on the 
basis of this analysis could be considered another important 
limitation. 
This study also provided an opportunity to evaluate the 
total ischemic burden as defined by the occ,rrence of silent 
myocardial ischemia during the initial 48 h after admission for 
u,'stable angina. Multivariate analyses in previous studies 
showed that the presence of silent ischemia was a predictor of 
subsequent major ischemic events (35,36). Recently, the Ad- 
visory Groups of the Council for Myocardial Ischemia nd 
Infarction (37) listed several ongoing studies of silent ischemia. 
Most of them (38-40) examine the use of treatment with 
beta-blockers, calcium channel antagonists or a combination of
these agents. 
We (6) previously demonstrated that the active thrombotic 
ar, d thrombolytic process in silent ischemia within the frame- 
g ork of unstable angina, also confirmed by earlier eports of 
others (41), is more than a vasoconstrictive phenomenon r an 
imbalance between demand and supply of blood to the heart. 
In this study, low molecular weight heparin plus aspirin was at 
least superior to aspirin or aspirin plus regular heparin in 
reducing the number of major and minor ischemic events after 
the development of silent ischemia, including bleeding risk. 
Other prospective valuations (42-44) of stronger anti- 
thrombotic therapies with direct antithrombins or anti-IIbflIIa 
glycoproteins--such as hirudin and monoclonal antibody, 
known as 7E3--are ongoing, but serious bleeding complica- 
tions are being seen. Therefore, low molecular weight heparin 
appears to be an important alternative to test. 
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